Changes in UCB's Board of Directors

Brussels (BELGIUM), 14 December 2007 at 7:00 AM CET - During its meeting of December 13, 2007, the Board of Directors examined the changes in its composition to occur by the next General Assembly on April 24, 2008, when the mandates of four Directors will come to an end. The Board is proposing candidates for their replacement.

The following Directors will leave on April 24, 2008:

• Alan Blinken, Board member since 2000, who will retire having reached the age limit applicable for Board members;
• Guy Keutgen, Board member since 1984, and Jean-Louis Vanherweghem, Board member since 1999, who at their own request, are not up for re-election;
• Georges Jacobs who, when retiring from his executive functions as CEO of the company in 2005, had accepted to chair the Board for a term of three years and is not seeking re-election. Georges Jacobs said: "After 39 years in this Company, 17 as CEO and 3 as Chairman of the Board, I think it is time to go and I am happy to have ensured during my chairmanship, a smooth transition towards its new destiny."

The Board decided to appoint Karel Boone, independent Director since 2000, as its Chairman to replace Georges Jacobs as from April 24, 2008. Karel Boone is Chairman of the Board of Directors of Lotus Bakeries, of Vandemoortele and Honorary Chairman of the FEB (Federation of Belgian Companies).

With a view to further broadening the skills of the Board, three candidates have been selected to be appointed as new Board members at the next Shareholders' meeting:

• Thomas Leysen, CEO of Umicore and next Chairman of the FEB (Federation of Belgian Companies), who will join the Board of UCB as of January 1, 2009;
• Jean-Pierre Kinet, Professor at Harvard Institute of Medicine and at the Beth Israel Deaconess Medical Center;
• Armand De Decker, President of the Belgian Senate.

The Board paid a special tribute to George Jacobs, CEO of UCB from 1987 to 2005 and Chairman of the Board of Directors since 2005. Under his chairmanship, thanks to his knowledge and long experience in the pharmaceutical and chemical activities of UCB, Georges Jacobs has been particularly helpful at supporting his successor Roch Doliveux, the CEO of UCB, in the transformation of UCB into a pure biopharmaceutical company.

The Board of Directors expressed its sincere thanks to Georges Jacobs for his long and outstanding career at UCB and for his major contribution to the fundamental transformation and growth of the UCB Group.

The Board also thanked Jean-Louis Vanherweghem, Guy Keutgen and Alan Blinken for their competent and valuable contribution to the Board of Directors.

About UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG.

Further information

Antje Witte, Vice-President Corporate Communications & Investor Relations, UCB Group

T +32.2.559.9414, Antje.witte@ucb-group.com

Mareike Mohr, Associate Director Investor Relations, UCB Group

T +32.2.559.9264, Mareike.mohr@ucb-group.com

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.